VEGFA and non-small cell lung carcinoma: We believe that VEGF could eventually be adopted into clinical practice for the prognostic evaluation of NSCLC if the findings of the present study can be corroborated by evidence from future studies, ideally with larger cohorts and longer follow-up periods (at least 6 months).